All the Drug Class Drugs
MMRV Vaccine. Live attenuated measles virus NLT 10^ 3 CCID, Live attenuated mumps virus NLT 10^ 4.4 CCID, Live attenuated rubella virus NLT 10^ 3 CCID, Varicella virus live attenuated >=10 ^ 3.3 PFU. AMP. (Pwdr. + solv. for sol. for inj.): 1, 10,
20, 50×0.5ml. Infan., child. 12 mnths.
up to 12 yrs.: two doses (each of 0.5
ml). The interv. should prefer. btwn. 6
wks.- 3 mnths. When the 1st dose is admin. at 11 mnths. of age, the 2nd
dose should be admin. within 3 mnths.
Under no circumst. should the dose
interv. be less than 4 wks.
Child. 9-11 months: In case an
epidemiological situation requires
vaccinating infants less than 12
months of age, the first dose can be
given as from 9 months of age. A 2nd
dose should be given three months
after the 1st dose. See lit.
Active immunis. against measles,
mumps, rubella, varicella in child. 12
mnth. - 12 yrs. includ. Use in infants 9-11
mnths. could be consid. under special
circumst.
C/I: Pts. acute sev. febr. illness.
Hypersens. to act. subst. or to neomycin.
Previous episodes of hypersens. after
admin. of MMR and/or varicella vacc.
Severe humoral/ cellular (primary/
acquired) immunodefic., e.g. severe
combined immunodef.,
agammaglobulinemia, AIDS or sympt.
HIV infec. or an age-specific CD4+
T-lymphocyte percentage in child.
below 12 mnths.: CD4+ <25%; children
btwn. 12-35 mnths.: CD4+ < 20%; child.
btwn. 36-59 mnths.: CD4+ < 15%
Preg., preg. should be avoid. for 1m.
follow. vacc.
